Primate adult brain cell autotransplantation produces behavioral and biological recovery in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced parkinsonian St. Kitts monkeys
- 8 March 2014
- journal article
- research article
- Published by Wiley in Journal of Comparative Neurology
- Vol. 522 (12) , 2729-2740
Abstract
The potential for “replacement cells” to restore function in Parkinson's disease has been widely reported over the past 3 decades, rejuvenating the central nervous system rather than just relieving symptoms. Most such experiments have used fetal or embryonic sources that may induce immunological rejection and generate ethical concerns. Autologous sources, in which the cells to be implanted are derived from recipients' own cells after reprogramming to stem cells, direct genetic modifications, or epigenetic modifications in culture, could eliminate many of these problems. In a previous study on autologous brain cell transplantation, we demonstrated that adult monkey brain cells, obtained from cortical biopsies and kept in culture for 7 weeks, exhibited potential as a method of brain repair after low doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) caused dopaminergic cell death. The present study exposed monkeys to higher MPTP doses to produce significant parkinsonism and behavioral impairments. Cerebral cortical cells were biopsied from the animals, held in culture for 7 weeks to create an autologous neural cell “ecosystem” and reimplanted bilaterally into the striatum of the same six donor monkeys. These cells expressed neuroectodermal and progenitor markers such as nestin, doublecortin, GFAP, neurofilament, and vimentin. Five to six months after reimplantation, histological analysis with the dye PKH67 and unbiased stereology showed that reimplanted cells survived, migrated bilaterally throughout the striatum, and seemed to exert a neurorestorative effect. More tyrosine hydroxylase-immunoreactive neurons and significant behavioral improvement followed reimplantation of cultured autologous neural cells as a result of unknown trophic factors released by the grafts. J. Comp. Neurol. 522:2729–2740, 2014.Keywords
Funding Information
- Axion Research Foundation
- St. Kitts Biomedical Research Foundation
- Foundation Swiss Parkinson
- Swiss National Funds (3100AO-103924)
This publication has 66 references indexed in Scilit:
- What is the potential of oligodendrocyte progenitor cells to successfully treat human spinal cord injury?BMC Neurology, 2011
- Timing ofSonic hedgehogandGli1expression segregates midbrain dopamine neuronsJournal of Comparative Neurology, 2011
- Melanocortin‐4 receptor expression in a vago‐vagal circuitry involved in postprandial functionsJournal of Comparative Neurology, 2009
- Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's diseaseProceedings of the National Academy of Sciences, 2008
- Highly efficient and large-scale generation of functional dopamine neurons from human embryonic stem cellsProceedings of the National Academy of Sciences, 2008
- Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined FactorsCell, 2007
- Apoptotic natural cell death in developing primate dopamine midbrain neurons occurs during a restricted period in the second trimester of gestationExperimental Neurology, 2007
- Selection of Embryonic Stem Cell-Derived Enhanced Green Fluorescent Protein-Positive Dopamine Neurons Using the Tyrosine Hydroxylase Promoter Is Confounded by Reporter Gene Expression in Immature Cell PopulationsStem Cells, 2007
- Time Course of Apoptotic Cell Death within Mesencephalic Cell Suspension Grafts: Implications for Improving Grafted Dopamine Neuron SurvivalExperimental Neurology, 2000
- FETAL NEURONAL GRAFTS IN MONKEYS GIVEN METHYLPHENYLTETRAHYDROPYRIDINEThe Lancet, 1986